Most of our members follow our articles on Croblanc, so you are not very surprised that we talk to you today about the Youtube channel Bloomberg Television! The videos that are broadcasted there have been of great interest to the internet for quite some time now. That's why we decided to make a post about it, because we are sure you will enjoy this new video.
Here is the last video of the youtube channel Bloomberg Television. It's called Lilly's New Weight-Loss Pill Underperforms in Study and as you can imagine, it's already of great interest to Internet users. You can find it right here.
And as expected, the last video of the Youtube channel Bloomberg Television is a hit on the first feedback we could read! It manages to interest a lot of internet users, which is not always easy considering the amount of content that can be found now on the internet as well as on applications such as TikTok, Facebook or Instagram.
There may be a case where you need to contact the videographer author of this video to give him your criticism, remarks or advice. You have 2 main ways to talk to a Youtuber, the most common way is by using the email address that is displayed on his Youtube channel (in the "About" section). However, not all youtubers have the time to reply to each of you, so you can also try to contact them on their social networks.
And here we are, we are almost at the end of this article, you have just discovered everything we knew about the video Lilly's New Weight-Loss Pill Underperforms in Study. In our platform, you can find other videos of Bloomberg Television, take a look at it occasionally, it's practical and it can allow you to find contents that you had never seen before on the web!
Friends, this is already the end of this little editorial, see you soon for a new article on Croblanc!
For your information, you can find below the description of the video Lilly's New Weight-Loss Pill Underperforms in Study published by the Youtube channel Bloomberg Television:
Eli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday morning, even though the company raised its yearly profit and sales outlook. In the study, patients taking the drug orforglipron, lost roughly 11% of their body weight, about 25 pounds. Bloomberg's Damian Garde reports.
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more.
Connect with Bloomberg Television on:
X: https://twitter.com/BloombergTV
Facebook: https://www.facebook.com/BloombergTelevision
Instagram: https://www.instagram.com/bloombergtv/
Connect with Bloomberg Business on:
X: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en
Reddit: https://www.reddit.com/r/bloomberg/
LinkedIn: https://www.linkedin.com/company/bloomberg-news/
More from Bloomberg:
Bloomberg Radio: https://twitter.com/BloombergRadio
Bloomberg Surveillance: https://twitter.com/bsurveillance
Bloomberg Politics: https://twitter.com/bpolitics
Bloomberg Originals: https://twitter.com/bbgoriginals
Watch more on YouTube:
Bloomberg Technology: https://www.youtube.com/@BloombergTechnology
Bloomberg Originals: https://www.youtube.com/@business
Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake
Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol
Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts